Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 02, 2015 12:12 AM ET


Company Overview of Oramed Pharmaceuticals Inc.

Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule that completed Phase IIa clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials for the treatment of type 2 diabetes. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

Hi-Tech Park 2/4


PO Box 39098

Jerusalem,  91390


Founded in 2002


972 2 566 0001


972 2 566 0004

Key Executives for Oramed Pharmaceuticals Inc.

Chief Executive Officer, President and Executive Director
Age: 41
Total Annual Compensation: $381.3K
Chief Financial Officer, Treasurer and Secretary
Age: 41
Total Annual Compensation: $193.8K
Chief Operating Officer and Vice President of Business Development
Age: 45
Total Annual Compensation: $199.2K
Chief Scientific Officer and Director
Age: 75
Total Annual Compensation: $271.3K
Compensation as of Fiscal Year 2014.

Oramed Pharmaceuticals Inc. Key Developments

Oramed Pharmaceuticals Inc. Submits Protocol to U.S. FDA for its Phase IIb Oral Insulin Study

Oramed Pharmaceuticals Inc. announced that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration (FDA). The submission was made under the company's existing Investigational New Drug (IND) application. The Phase IIb study of ORMD-0801 for type 2 diabetics is designed to generate ample data for both efficacy and safety endpoints. The double-blind, randomized study will recruit approximately 180 patients and has a 28-day treatment period. The study has already received Institutional Review Board (IRB) approval and patient enrollment is expected to start in the short term.

Oramed Pharmaceuticals Inc. Presents at Oppenheimer16th Annual Israeli Conference, May-10-2015 01:45 PM

Oramed Pharmaceuticals Inc. Presents at Oppenheimer16th Annual Israeli Conference, May-10-2015 01:45 PM. Venue: David Intercontinental Hotel, Tel-Aviv, Israel. Speakers: Nadav Kidron, Chief Executive Officer, President and Executive Director.

Oramed Pharmaceuticals Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 12:30 PM

Oramed Pharmaceuticals Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 12:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Michael Berelowitz, Chairman of Scientific Advisory Board, Director and Member of Compensation Committee.

Similar Private Companies By Industry

Company Name Region
MedWell Laboratories Ltd. Middle East/Africa
LycoRed Ltd. Middle East/Africa
Palsamed (PBS) Ltd. Middle East/Africa
Ora Bio Ltd. Middle East/Africa
Chemagis Ltd. Middle East/Africa

Recent Private Companies Transactions

Private Placement
November 3, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oramed Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at